mediguide4u logo
mediguide4u
NavigationHomeAbout UsHealth GuidesHealth ToolsQuizzesMedical BoardFAQContact
Account
LoginRegister
Heart & Cardiometabolic HealthHepatic & Metabolic Health

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Stages, SGPT/ALT Tests, FibroScan, and Evidence-Based Dietary Reversal

A comprehensive clinical roadmap to understanding and reversing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Covers hepatic fat accumulation, elevated ALT/SGPT interpretation, FibroScan CAP scores, insulin resistance, and an actionable evidence-based dietary plan.

R
Written by Dr. Randhir Sud, MBBS, MD, DM, MAMSChairman, Institute of Digestive & Hepatobiliary Sciences, Medanta – The Medicity
Medically Reviewed by Dr. Rommel Tickoo, MBBS, MD✓ Verified
MBBS, MD (Internal Medicine)• Reviewed October 2026•Medical Review Board
Published: 2026-10-18Reviewed: October 2026Updated: 2026-10-31 10 min read 1437 Views
Listen to this guide Audio Edition

Hands-free audio narration

Educational Health Notice

This educational guide is researched in accordance with our Editorial Policy and public health guidelines. It is not personal medical advice. For clinical questions, read our Medical Disclaimer or consult a qualified healthcare provider.

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) diagnostic ultrasound scan and medical consultation

Quick Summary & Key Findings

Metabolic Dysfunction-Associated Steatotic Liver Disease, which was once called Non‑Alcoholic Fatty Liver Disease is found when fat drops gather in than five per cent of liver cells in people who have at least one heart‑related risk factor such as big belly, trouble with insulin, type two diabetes, bad cholesterol levels or high blood pressure and who do not drink much alcohol. If the fat build up is mild (Grade 1) it can be fully undone by losing seven to ten per cent of body weight steadily and by eating a diet that has plenty of one‑unsaturated fats and soluble fibre.. If the fat build up is not stopped it can quietly grow into Metabolic Dysfunction-Associated Steatohepatitis, then into more serious scarring of the liver and eventually, into permanent cirrhosis. Metabolic Dysfunction-Associated Steatotic Liver Disease can become irreversible if left unchecked.

One of the most commonly shrugged off findings in hepatology and internal medicine is mild fatty liver on ultrasound or an ALT (SGPT) of 54U/L on annual executive screening. It is commonly assumed that if you don’t drink alcohol your liver is fine. This has caused Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or previously NAFLD) to become the number one cause of chronic liver disease worldwide. It affects an estimated 32-38% of adults and over 65% of patients with type 2 diabetes.

In 2023 the name was officially changed to MASLD by multi-national liver associations to emphasise the cause of the disease. This is due to it being caused by cardiometabolic dysfunction. This begins with insulin resistance in the muscles and adipose tissue. When these tissues become insulin resistant, hormone sensitive lipase causes the breakdown of fat stores in adipose tissue. This causes free fatty acids to accumulate in the portal vein. The liver cells then become overloaded with these fats and will accumulate them in the form of triglycerides. As there are no pain receptors in the liver, fat will accumulate without causing the patient symptoms of jaundice or pain.

There are no pain receptors in the liver meaning that fatty liver / MASLD / NAFLD can develop without symptoms for many years.

Pathophysiology and the Consensus Nomenclature: Why NAFLD Is Now MASLD

The reclassification of NAFLD to MASLD was established by a global consensus of hepatology societies (AASLD, EASL, and ALEH) to replace exclusionary, potentially stigmatizing language with affirmative diagnostic cardiometabolic criteria:
Confirming hepatic steatosis using imaging techniques such as ultrasound, CT, MRI or FibroScan, and presence of at least one of the following cardiometabolic risk factors: a. BMI ≥ 25 kg/m2 (≥ 23 kg/m2 in Asian populations) or waist circumference > 94cm (male) / > 80cm (female). b. Fasting serum glucose ≥ 100mg/dL or Type 2 diabetes. c. Blood pressure ≥ 130/85mmHg or taking antihypertensives. d. Plasma triglycerides ≥ 150mg/dL or taking lipids lowering agents. e. Serum HDL cholesterol <40mg/dL (male) / <50mg/dL (female).
De Novo Lipogenesis (DNL): Hyperinsulinemia during an insulin resistant state causes increased activity of transcription factors SREBP-1c and ChREBP within the hepatocyte which accelerates the enzymatic conversion of simple dietary sugars (particularly fructose) into saturated fatty acids. This can occur even in a calorie restricted state.
Mitochondrial Lipotoxicity Excess free fatty acids cause reactive oxygen species (ROS) formation due to lipid droplet storage capacity being exceeded. These cause endoplasmic reticulum stress, mitochondrial cristae disruption and DAMPs are released which cause recruitment of inflammatory Kupffer cells.
Kupffer Cell and Stellate Cell Activation During chronic oxidative damage quiescent hepatic stellate cells become activated contractile myofibroblasts that deposit excessive type I and type III collagen fibrils in the space of Disse causing hepatic fibrosis.

Histological and Ultrasound Stages of Steatotic Liver Disease

Clinical StageHistological FeaturesCAP Score (FibroScan)Liver Stiffness (kPa)Reversibility Potential
Grade 1: Mild Simple Steatosis5% to 33% of hepatocytes infiltrated by microvesicular/macrovesicular lipid vacuoles; zero lobular inflammation.238 to 259 dB/m< 6.0 kPa100% Reversible with 5% weight loss and dietary correction within 3 to 6 months.
Grade 2: Moderate Steatosis34% to 66% hepatocyte fat involvement; diffuse hyperechoic liver texture on ultrasound with mild vascular blurring.260 to 290 dB/m6.0 to 7.0 kPaFully reversible with 7% to 10% sustained weight reduction and aerobic conditioning.
Grade 3: Severe Steatosis> 66% hepatocyte fat infiltration; marked attenuation of acoustic ultrasound beam with non-visualization of deep diaphragm.> 290 dB/m7.0 to 8.2 kPaReversible, but carries high risk of spontaneous transition to MASH.
MASH (Steatohepatitis)Hepatocyte ballooning degeneration, Mallory-Denk bodies, neutrophilic lobular infiltrates, with or without perisinusoidal fibrosis.> 300 dB/m8.2 to 12.0 kPa (F2-F3)Inflammation reversible; early collagen cross-linking can remodel with intensive medical therapy.
Compensated Cirrhosis (F4)Extensive fibrous septae bridging portal triads and central veins; regenerative parenchymal nodules.Variable due to parenchymal loss> 12.5 to 15.0 kPaStructural architecture irreversible; focus shifts to portal hypertension screening and HCC surveillance.

Diagnostic Workup: Decoding Transaminases (ALT/SGPT), AST, and the FIB-4 Index

A frequent clinical pitfall is assuming normal liver enzymes exclude progressive liver disease. Up to 50% of patients with advanced MASH maintain transaminases within conventional commercial laboratory reference ranges:
ALT (SGPT) True Clinical Reference Ranges – Whilst many lab reference ranges will state ‘normal’ ALT levels as being up to 45-55 U/L, the American College of Gastroenterology provides true reference ranges for ALT of 33 U/L (men) and 25 U/L (women). Any persistent elevations above these values should prompt investigation of the liver.
AST/ALT De Ritis Ratio: In simple MASLD and early MASH ALT is usually higher than AST (ratio <1.0). However as fibrosis progresses, AST levels increase due to decreased hepatic sinusoidal clearance of AST. The resulting AST/ALT ratio will be greater than 1.0. An AST/ALT ratio >1.5 should raise strong suspicion of advanced fibrosis (F3) or cirrhosis (F4).
Serum Ferritin and Transferrin Saturation Serum ferritin levels are mildly raised (300-800ng/ml) and transferrin saturation levels are normal (<45%). This indicates DIOS due to systemic inflammatory processes and hepcidin dysregulation rather than hereditary haemochromatosis.
FIB-4 Non-Invasive Score: Age, AST, ALT & Platelets are used to calculate this score. FIB-4 = (Age x AST) / (Platelet count x sqrt(ALT)). If this score is below 1.30 (<2.0 in patients >65 years of age) it has a 90% negative predictive value meaning we can safely exclude those with advanced fibrosis (F3/F4). Patients with a score above 2.67 are at high risk and must be referred for FibroScan or hepatology immediately.

New Consensus Nomenclature (AASLD/EASL), The FIB-4 Score & FibroScan CAP Diagnostics

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), is a liver disease associated with metabolic syndrome and affects over 30% of the adult world population. In 2023, a consensus was agreed upon by global hepatology societies (AASLD, EASL, ALEH) that MASLD requires evidence of liver steatosis either by imaging or histology alongside one or more of the 5 cardiometabolic risk factors; overweight/obesity, impaired fasting glucose/type 2 diabetes, hypertension, hypertriglyceridaemia and reduced HDL-C. Steatosis can progress to Metabolic Dysfunction-Associated Steatohepatitis (MASH) when lipotoxicity occurs in hepatocytes causing ballooning, lobular inflammation and progressive perisinusoidal collagen deposition.
FIB-4 Non-Invasive Fibrosis Index. This is a commonly used first line screening test. It uses Age, AST, ALT and Platelet counts. Low Risk / Excludes advanced fibrosis (FIB-4 <1.30, or <2.0 for patients over 65 years old. Negative predictive value >90%). Intermediate Risk, 1.30-2.67. Second line tests are required. High Risk, FIB-4 >2.67. Indicates advanced bridging fibrosis (F3-F4). Referral to hepatology is required.
Vibration-Controlled Transient Elastography (FibroScan). Point-of-care ultrasound based elastography. CAP (dB/m): Mild liver steatosis (S1) >=248, Moderate liver steatosis (S2) >=268, Severe liver steatosis (S3) >=280 dB/m. LSM (kPa): Normal (F0-F1) <7.0 kPa, Moderate (F2) 7.0-9.5 kPa, Advanced (F3) 9.5-12.5 kPa, Cirrhosis (F4) >=12.5 kPa.
Serum Transaminase Pitfalls: Up to 50% of patients with severe biopsy-proven MASH will have normal serum ALT (SGPT) and AST levels. This emphasizes the importance of not relying on normal liver function panels when considering whether a patient has progressive liver disease when they have metabolic syndrome.
Cardiovascular death is the leading cause of mortality in MASLD patients with CVD (myocardial infarction and stroke) being the main cause of death followed by extra-hepatic malignancies and complications of cirrhosis.

Biopsy-Proven Weight Loss Thresholds, The Mediterranean Diet & FDA-Approved Resmetirom

Reversing hepatic steatosis and halting fibrotic scarring requires achieving specific weight-reduction thresholds supported by nutritional optimization and newly approved targeted hepatoprotective pharmacotherapy.
Biopsy-confirmed weight loss milestones From seminal clinical trials using liver biopsy, it has been confirmed that a reduction in total body weight by 3-5% or more leads to significant improvements in hepatic steatosis. A total body weight reduction by 7% or more leads to complete resolution of histological changes associated with MASH (ballooned hepatocytes and lobular inflammation). Finally, a total body weight reduction by 10% or more can lead to regression and remodelling of existing liver fibrosis.
Low Fructose Mediterranean Diet: Remove all HFCS and sucrose sweetened drinks. High fructose will be converted in the liver without PFK control causing rapid DNL and fat build up in the liver. Replace with natural foods containing polyphenols and monounsaturated fats.
1st FDA-approved MASH therapy: A landmark Phase 3 trial (MAESTRO-NASH Trial; NEJM 2024) demonstrated 30% MASH resolution and a reduction of fibrosis by ≥1 stage in 26% of patients without deterioration in fibrosis using the liver targeted Thyroid Hormone Receptor-beta (THR-beta) partial agonist resmetirom (80-100mg/day).
GLP-1 Receptor Agonist & SGLT2i Synergy: All three agents (Semaglutide, Tirzepatide & Empagliflozin) cause a significant reduction in liver fat, reduction in transaminases and weight loss. This provides essential cardiometabolic and hepatic protection for those with coexisting type 2 diabetes/obesity.

Frequently Asked Questions

R
Clinical Reviewer License Verified

Dr. Rommel Tickoo, MBBS, MD

Director, Internal Medicine & Infectious Diseases, Max Super Speciality Hospital, Saket • MBBS, MD (Internal Medicine)
Medical Review Board

Dr. Rommel Tickoo is the Director of Internal Medicine at Max Super Speciality Hospital, Saket, New Delhi. With over 24 years of experience in adult primary care, infectious disease management, routine screenings, and fever diagnostics, he reviews mediguide4u preventive care and vaccination protocols.

License ID: DMC-12876
Director, Department of Internal Medicine, Max Super Speciality Hospital, Saket, New Delhi
Medically evaluated on October 2026View Dr. Profile, Verified Credentials & Articles

References & Clinical Resources

  1. Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023). [Access Resource Link] — Hepatology / Journal of Hepatology / Annals of Hepatology
  2. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease (2023). [Access Resource Link] — Hepatology
  3. Harrison SA, Bedossa P, Guy CD, et al.. A Controlled Trial of Resmetirom in Nonalcoholic Steatohepatitis with Fibrosis (2024). [Access Resource Link] — The New England Journal of Medicine (NEJM)
  4. Younossi ZM, Golabi P, Paik JM, et al.. Global epidemiology of non-alcoholic fatty liver disease / MASLD: meta-analytic assessment of prevalence and incidence (2023). [Access Resource Link] — The Lancet Gastroenterology & Hepatology
Article Tools & Sharing:
Educational Resources

Related Healthcare Guides

Patient Community Doctor Reviewed

Reader Reviews & Clinical Q&A

Real experiences, reader questions, and verified physician guidance.

5.0 out of 5 (0 reviews)

Leave a Review or Ask a Medical Question

5 / 5 Stars
* Reviews are reviewed by our clinical editorial team in accordance with our medical policies.